See more : Rentokil Initial plc (RTO) Income Statement Analysis – Financial Results
Complete financial analysis of ImmunityBio, Inc. (IBRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmunityBio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Alankit Limited (ALANKIT.NS) Income Statement Analysis – Financial Results
- Prime Urban Development India Limited (PRIMEURB.BO) Income Statement Analysis – Financial Results
- Borders & Southern Petroleum plc (BDRSF) Income Statement Analysis – Financial Results
- Hercules Hoists Limited (HERCULES.BO) Income Statement Analysis – Financial Results
- Komax Holding AG (KMAAF) Income Statement Analysis – Financial Results
ImmunityBio, Inc. (IBRX)
About ImmunityBio, Inc.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 622.00K | 240.00K | 934.00K | 605.00K | 2.20M | 47.00K | 45.00K | 44.00K | 236.00K | 641.00K | 600.00K |
| Cost of Revenue | 0.00 | 24.19M | 0.00 | 9.15M | 9.01M | -3.11M | 0.00 | 0.00 | 0.00 | 0.00 | 253.00K |
| Gross Profit | 622.00K | -23.95M | 934.00K | -8.54M | -6.81M | 3.16M | 45.00K | 44.00K | 236.00K | 641.00K | 347.00K |
| Gross Profit Ratio | 100.00% | -9,980.00% | 100.00% | -1,411.90% | -309.26% | 6,717.02% | 100.00% | 100.00% | 100.00% | 100.00% | 57.83% |
| Research & Development | 232.37M | 248.15M | 195.96M | 139.51M | 112.00M | 53.42M | 39.78M | 26.55M | 11.43M | 1.60M | 446.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.39M | 57.12M | 95.39M | 227.68M | 4.33M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.07M | -3.30M | -1.00M | -1.47M | 0.00 | 0.00 |
| SG&A | 129.62M | 102.71M | 135.26M | 71.32M | 46.46M | 35.46M | 53.82M | 94.39M | 226.21M | 4.33M | 2.42M |
| Other Expenses | 886.00K | -736.00K | 193.00K | 1.49M | -534.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 362.87M | 350.86M | 331.21M | 210.83M | 158.45M | 88.88M | 93.60M | 120.94M | 237.64M | 5.92M | 2.87M |
| Cost & Expenses | 362.87M | 350.86M | 331.21M | 210.83M | 158.45M | 98.44M | 99.17M | 124.54M | 239.11M | 6.24M | 2.87M |
| Interest Income | 863.00K | 2.71M | 836.00K | 1.73M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K |
| Interest Expense | 129.20M | 63.52M | 14.85M | 9.07M | 5.92M | 433.00K | 618.00K | 66.00K | 0.00 | 0.00 | 463.00K |
| Depreciation & Amortization | 18.51M | 24.19M | 19.12M | 9.15M | 9.01M | 9.56M | 5.57M | 3.61M | 1.47M | 128.00K | 4.00K |
| EBITDA | -436.18M | -335.51M | -315.38M | -187.93M | -142.27M | -86.74M | -90.73M | -117.71M | -235.71M | -5.68M | -1.58M |
| EBITDA Ratio | -70,125.72% | -143,324.17% | -33,865.52% | -32,252.56% | -6,356.77% | -189,008.51% | -207,897.78% | -274,756.82% | -100,594.92% | -949.14% | -263.17% |
| Operating Income | -362.25M | -351.30M | -330.28M | -220.88M | -156.25M | -98.39M | -99.12M | -124.50M | -238.88M | -6.21M | -2.27M |
| Operating Income Ratio | -58,239.55% | -146,374.17% | -35,361.88% | -36,509.09% | -7,095.87% | -209,338.30% | -220,266.67% | -282,954.55% | -101,218.64% | -969.11% | -378.17% |
| Total Other Income/Expenses | -221.64M | -65.99M | -19.56M | -25.36M | -3.95M | 1.66M | 2.20M | 3.12M | 1.70M | -609.00K | 223.00K |
| Income Before Tax | -583.89M | -417.29M | -349.84M | -226.03M | -160.26M | -96.73M | -96.92M | -121.38M | -237.18M | -6.21M | -2.05M |
| Income Before Tax Ratio | -93,873.31% | -173,869.17% | -37,456.00% | -37,360.83% | -7,278.07% | -205,806.38% | -215,368.89% | -275,865.91% | -100,498.73% | -969.11% | -341.00% |
| Income Tax Expense | -40.00K | 34.00K | 9.00K | -1.85M | -105.00K | -503.00K | -493.00K | -572.00K | -301.00K | 1.00K | 1.00K |
| Net Income | -583.20M | -417.32M | -349.85M | -224.19M | -160.16M | -96.23M | -96.42M | -120.81M | -236.88M | -6.21M | -2.05M |
| Net Income Ratio | -93,761.41% | -173,883.33% | -37,456.96% | -37,055.70% | -7,273.30% | -204,736.17% | -214,273.33% | -274,565.91% | -100,371.19% | -969.27% | -341.17% |
| EPS | -1.15 | -1.04 | -0.90 | -0.59 | -0.42 | -1.22 | -1.20 | -1.47 | -3.31 | -0.02 | -2.57 |
| EPS Diluted | -1.15 | -1.04 | -0.90 | -0.59 | -0.42 | -1.22 | -1.20 | -1.47 | -3.31 | -0.02 | -2.57 |
| Weighted Avg Shares Out | 508.64M | 399.90M | 389.23M | 383.18M | 383.18M | 79.13M | 80.58M | 81.98M | 71.52M | 315.73M | 797.11K |
| Weighted Avg Shares Out (Dil) | 508.64M | 399.90M | 389.23M | 383.18M | 383.18M | 79.13M | 80.58M | 81.98M | 71.52M | 315.73M | 797.11K |
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit
BENSALEM, Pa. , Aug. 4, 2023 /PRNewswire/ -- Law Offices of Howard G.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of §§10(b) and...
IBRX SHAREHOLDER ALERT: Jakubowitz Law Reminds ImmunityBio Shareholders of a Lead Plaintiff Deadline of August 29, 2023
NEW YORK , Aug. 4, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/immunitybio-class-action-loss-submission-form/?id=42953&from=4 The...
ImmunityBio Names Enrique Diloné as Chief Technology Officer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has named Enrique Diloné, Ph.D., to the newly created role of Chief Technology Officer. With more than three decades of pharmaceutical manufacturing expertise, Dr. Diloné...
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of §§10(b) and...
IBRX LAWSUIT ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Aug. 3, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ImmunityBio...
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of §§10(b) and...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ImmunityBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 29, 2023 - (NASDAQ: IBRX)
NEW YORK , Aug. 2, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc.. Shareholders who purchased shares of IBRX during the class period listed are encouraged to contact the firm regarding possible...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of §§10(b) and...
IBRX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 29, 2023 in the Class Action Filed on Behalf of ImmunityBio, Inc. Shareholders
NEW YORK , Aug. 1, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) alleging that the Company violated federal securities laws. Class Period:...
Source: https://incomestatements.info
Category: Stock Reports